Kumar Srinivasan
Director/Board Member presso TRANSCENTA HOLDING LIMITED
Patrimonio netto: 6 943 $ in data 30/04/2024
Profilo
Kumar Srinivasan is currently the President & Chief Executive Officer at Wugen, Inc. He is also a Director at Pulmotect, Inc. and an Independent Non-Executive Director at Transcenta Holding Ltd.
Previously, he worked as the Chief Business Officer & Executive Vice President at Turning Point Therapeutics, Inc. Dr. Srinivasan holds a doctorate degree from Case Western Reserve University, undergraduate and graduate degrees from the University of Madras, and an MBA from The University of Chicago Booth School of Business.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
06/04/2023 | 30 000 ( 0.01% ) | 6 943 $ | 30/04/2024 |
Posizioni attive di Kumar Srinivasan
Società | Posizione | Inizio |
---|---|---|
TRANSCENTA HOLDING LIMITED | Director/Board Member | 19/12/2022 |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Director/Board Member | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Chief Executive Officer | 13/03/2023 |
Precedenti posizioni note di Kumar Srinivasan
Società | Posizione | Fine |
---|---|---|
TURG POIN | Corporate Officer/Principal | - |
Formazione di Kumar Srinivasan
Case Western Reserve University | Doctorate Degree |
University of Madras | Graduate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
TRANSCENTA HOLDING LIMITED | Health Technology |
Aziende private | 3 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
- Borsa valori
- Insiders
- Kumar Srinivasan